Man Group’s ADMA Biologics ADMA Stock Holding History

Man Group’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$185K	Buy	+22,053	New	+$201K	﹤0.01%	2273
2025 Q4	–	Sell	-24,319	Closed	-$357K	–	2230
2025 Q3	$357K	Sell	24,319 -104,099	-81%	-$1.78M	﹤0.01%	1954
2025 Q2	$2.34M	Sell	128,418 -29,727	-19%	-$606K	﹤0.01%	1346
2025 Q1	$3.14M	Sell	158,145 -587,155	-79%	-$10.2M	0.01%	1192
2024 Q4	$12.8M	Buy	745,300 +561,507	+306%	+$10.6M	0.03%	634
2024 Q3	$3.67M	Buy	+183,793	New	+$2.86M	0.01%	1131
2024 Q2	–	Sell	-25,598	Closed	-$169K	–	2007
2024 Q1	$169K	Buy	+25,598	New	+$140K	﹤0.01%	2032
2022 Q2	–	Sell	-91,717	Closed	-$168K	–	2028
2022 Q1	$168K	Buy	+91,717	New	+$143K	﹤0.01%	1973

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Man Group's ADMA Position: Q2 2026 in Review

Man Group opened a new position in ADMA Biologics (ADMA) in Q2 2026: 22,053 shares worth $185K. The stake represents ﹤0.01% of the portfolio and ranks #2273 among its holdings. This is a return to the name: Man Group previously reported a position in ADMA as recently as Q3 2025.

Man Group first reported a position in ADMA in Q1 2022 and has held it in 8 quarters since. The position peaked at $12.8M in Q4 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Man Group held 22,053 shares of ADMA Biologics worth $185K as of Q2 2026.
ADMA Biologics was a new Man Group position in Q2 2026.
ADMA Biologics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2273 holding.
Man Group first reported a position in ADMA Biologics in Q1 2022 and has held it in 8 quarters since.
Man Group's ADMA Biologics position peaked at $12.8M in Q4 2024.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.